My HappyStock
Log in to track your learning progress.
US Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
MRNA
Moderna, Inc. (MRNA)
Average score 4.3 F
Preference —
Six company scores
Average score
Company growth5 / 10
Vaccine sales rebound abroad after COVID-era decline
Profitability2 / 10
High R&D costs and lower vaccine sales drive losses
Financial stability5 / 10
Large liquidity buffer, but debt and cash burn have risen
Economic moat6 / 10
mRNA platform, patents and manufacturing know-how
Future outlook7 / 10
Flu vaccine approval and cancer-vaccine trial progress
Valuation1 / 10
Losses persist while the share price prices in major success
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- COVID-19 Vaccines 94.74%
Spikevax and mNEXSPIKE COVID vaccines
- RSV Vaccines 2.21%
mRESVIA vaccine against respiratory syncytial virus
- Other Revenue 3.05%
Grants, collaborations, royalties and standby manufacturing
Revenue by region
- United States 59.41%
- International 40.59%
Key metrics
| Revenue CAGR (5 years) | 19% |
|---|---|
| Operating income CAGR (5 years) | - |
| Net income CAGR (5 years) | - |
| Operating margin (5-year avg.) | -44% |
| ROE (5-year avg.) | 22% |
| ROA (5-year avg.) | 9% |
| Beta (5 years) | 1.17 |
| MDD (5 years) | -94% |
| Payout ratio (5-year avg.) | - |
| P/E | - |
| Forward P/E | - |
| PEG | - |